Literature DB >> 6584912

A carbohydrate side chain on hemagglutinins of Hong Kong influenza viruses inhibits recognition by a monoclonal antibody.

J J Skehel, D J Stevens, R S Daniels, A R Douglas, M Knossow, I A Wilson, D C Wiley.   

Abstract

A single amino acid substitution, Asp-63 to Asn-63, was detected in the hemagglutinin of an antigenic variant of the 1968 Hong Kong (H3) influenza virus that was selected by growth of the wild-type virus in the presence of a monoclonal antibody. The mutation generates an oligosaccharide attachment site, Asn-Cys-Thr at residues 63-65, that is glycosylated. Immunoprecipitation experiments with extracts from variant virus-infected cells prepared in the presence or absence of tunicamycin, which inhibits glycosylation, demonstrate that addition of the new oligosaccharide side chain is required to prevent reaction with the monoclonal antibody. Similar experiments with the virus of the 1969 Hong Kong influenza epidemic, A/England/878/69, which also contains a hemagglutinin glycosylated at residue 63, support this conclusion and provide evidence for the epidemiological significance of carbohydrate-mediated modifications of hemagglutinin antigenicity.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6584912      PMCID: PMC345004          DOI: 10.1073/pnas.81.6.1779

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  17 in total

1.  Continuous cultures of fused cells secreting antibody of predefined specificity.

Authors:  G Köhler; C Milstein
Journal:  Nature       Date:  1975-08-07       Impact factor: 49.962

2.  Future influenza vaccines and the use of genetic recombinants.

Authors:  E D Kilbourne
Journal:  Bull World Health Organ       Date:  1969       Impact factor: 9.408

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Amino acid sequence changes in the haemagglutinin of A/Hong Kong (H3N2) influenza virus during the period 1968--77.

Authors:  W G Laver; G M Air; T A Dopheide; C W Ward
Journal:  Nature       Date:  1980-01-31       Impact factor: 49.962

5.  Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation.

Authors:  D C Wiley; I A Wilson; J J Skehel
Journal:  Nature       Date:  1981-01-29       Impact factor: 49.962

6.  A better cell line for making hybridomas secreting specific antibodies.

Authors:  M Shulman; C D Wilde; G Köhler
Journal:  Nature       Date:  1978-11-16       Impact factor: 49.962

7.  Antigenic drift between the haemagglutinin of the Hong Kong influenza strains A/Aichi/2/68 and A/Victoria/3/75.

Authors:  M Verhoeyen; R Fang; W M Jou; R Devos; D Huylebroeck; E Saman; W Fiers
Journal:  Nature       Date:  1980-08-21       Impact factor: 49.962

8.  Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion.

Authors:  G Köhler; C Milstein
Journal:  Eur J Immunol       Date:  1976-07       Impact factor: 5.532

9.  Antigenic drift in the hemagglutinin of the Hong Kong influenza subtype: correlation of amino acid changes with alterations in viral antigenicity.

Authors:  M J Sleigh; G W Both; P A Underwood; V J Bender
Journal:  J Virol       Date:  1981-03       Impact factor: 5.103

10.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

View more
  197 in total

Review 1.  The evolution of human influenza viruses.

Authors:  A J Hay; V Gregory; A R Douglas; Y P Lin
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-12-29       Impact factor: 6.237

2.  Mechanism of binding of surfactant protein D to influenza A viruses: importance of binding to haemagglutinin to antiviral activity.

Authors:  K L Hartshorn; M R White; D R Voelker; J Coburn; K Zaner; E C Crouch
Journal:  Biochem J       Date:  2000-10-15       Impact factor: 3.857

3.  Posttranslational side chain modification of a viral epitope results in diminished recognition by specific T cells.

Authors:  J K Larson; L Otvos; H C Ertl
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

4.  Glycosylation requirements for intracellular transport and function of the hemagglutinin of influenza virus.

Authors:  P J Gallagher; J M Henneberry; J F Sambrook; M J Gething
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

Review 5.  Viral glycoprotein heterogeneity-enhancement of functional diversity.

Authors:  I T Schulze; I D Manger
Journal:  Glycoconj J       Date:  1992-04       Impact factor: 2.916

6.  Evolution and adaptation of hemagglutinin gene of human H5N1 influenza virus.

Authors:  Kaifa Wei; Yanfeng Chen; Juan Chen; Lingjuan Wu; Daoxin Xie
Journal:  Virus Genes       Date:  2012-06       Impact factor: 2.332

7.  Post-translational modifications in insect cells.

Authors:  H D Klenk
Journal:  Cytotechnology       Date:  1996-01       Impact factor: 2.058

8.  Glycosylation at 158N of the hemagglutinin protein and receptor binding specificity synergistically affect the antigenicity and immunogenicity of a live attenuated H5N1 A/Vietnam/1203/2004 vaccine virus in ferrets.

Authors:  Weijia Wang; Bin Lu; Helen Zhou; Amorsolo L Suguitan; Xing Cheng; Kanta Subbarao; George Kemble; Hong Jin
Journal:  J Virol       Date:  2010-04-28       Impact factor: 5.103

9.  A computational analysis of the antigenic properties of haemagglutinin in influenza A H3N2.

Authors:  William D Lees; David S Moss; Adrian J Shepherd
Journal:  Bioinformatics       Date:  2010-04-13       Impact factor: 6.937

10.  The evolutionary dynamics of influenza A virus adaptation to mammalian hosts.

Authors:  S Bhatt; T T Lam; S J Lycett; A J Leigh Brown; T A Bowden; E C Holmes; Y Guan; J L N Wood; I H Brown; P Kellam; O G Pybus
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-02-04       Impact factor: 6.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.